These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27557840)

  • 1. Claims for disease-modifying therapy by Alberta non-insured health benefits clients.
    Barnabe C; Healy B; Portolesi A; Kaplan GG; Hemmelgarn B; Weaselhead C
    BMC Health Serv Res; 2016 Aug; 16(1):430. PubMed ID: 27557840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-modifying antirheumatic drug initiation among patients newly diagnosed with rheumatoid arthritis.
    Bonafede M; Johnson BH; Shah N; Harrison DJ; Tang D; Stolshek BS
    Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP279-SP285. PubMed ID: 30020740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.
    Curtis JR; Chastek B; Becker L; Quach C; Harrison DJ; Yun H; Joseph GJ; Collier DH
    J Manag Care Spec Pharm; 2015 Apr; 21(4):318-29. PubMed ID: 25803765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis.
    Boytsov NN; Bhattacharya R; Saverno K; Dixon L; Abbott PL; Zhang X; Gaich CL; Nair R
    J Manag Care Spec Pharm; 2019 Aug; 25(8):879-887. PubMed ID: 31347977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the response and economic burden of rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs in Taiwan using the National Health Insurance Research Database (NHIRD).
    Shi Q; Li KJ; Treuer T; Wang BCM; Gaich CL; Lee CH; Wu WS; Furnback W; Tang CH
    PLoS One; 2018; 13(4):e0193489. PubMed ID: 29624580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
    Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
    Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N; Lee YC; Shah N; Harrison DJ
    Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan.
    Katada H; Yukawa N; Urushihara H; Tanaka S; Mimori T; Kawakami K
    Clin Rheumatol; 2015 May; 34(5):949-56. PubMed ID: 24420724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refining a Claims-based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis.
    Popp RA; Rascati K; Davis M; Patel U
    Pharmacotherapy; 2018 Feb; 38(2):172-180. PubMed ID: 29197108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database.
    Cho SK; Sung YK; Choi CB; Kwon JM; Lee EK; Bae SC
    Rheumatol Int; 2013 Dec; 33(12):2985-92. PubMed ID: 23918169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Guideline-Orientated Prescription of Disease-Modifying Drugs in Patients with Rheumatoid Arthritis - an Analysis Based on Social Health Insurance Claims Data].
    Neubauer S; Zeidler H; Linder R; Zeidler J
    Dtsch Med Wochenschr; 2019 Jun; 144(12):e70-e79. PubMed ID: 30654405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geographic Variation in the Quality and Cost of Care for Patients with Rheumatoid Arthritis.
    Shafrin J; Ganguli A; Gonzalez YS; Shim JJ; Seabury SA
    J Manag Care Spec Pharm; 2016 Dec; 22(12):1472-1481. PubMed ID: 27882832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims.
    Curtis JR; Schabert VF; Harrison DJ; Yeaw J; Korn JR; Quach C; Yun H; Joseph GJ; Collier DH
    Clin Ther; 2014 Jul; 36(7):996-1004. PubMed ID: 25012729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antirheumatic Medicine Prescribing Patterns and Direct Medicine Costs in the South African Private Health Sector.
    Olivier N; Lubbe M; Joubert R; Naudé A; Burger J
    Value Health Reg Issues; 2018 Sep; 16():99-105. PubMed ID: 30227362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wide difference in biologics usage and expenditure for the treatment of patients with rheumatoid arthritis in each prefecture in Japan analyzed using "National Database of Health Insurance Claims and Specific Health Checkups of Japan".
    Kamata Y; Minota S
    Rheumatol Int; 2018 Apr; 38(4):663-668. PubMed ID: 29204683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of first-line biological treatment in patients with rheumatoid arthritis: Results from an observational study.
    Angelici L; Addis A; Agabiti N; Kirchmayer U; Davoli M; Belleudi V
    Medicine (Baltimore); 2021 May; 100(19):e25943. PubMed ID: 34106665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.